In 2021, over half of the FDA’s new drug approvals were for orphan or rare diseases. While orphan products are one of the fastest-growing areas of drug development, it can be hard to find detailed data on the market, and expert insights on potential change to the regulatory environment.
Our Orphan Drug Report 2022 addresses these challenges, drawing on the breadth and depth of data available across the Evaluate portfolio to answer some of the big questions about this increasingly competitive – and lucrative space.
Download our infographic for highlights from the full report.
Download Now
Share
Related Blogs
Understand the context. Data-driven news and analysis for the pharma, biotech and medtech sectors.
The US Healthcare system is a vast, unwieldy beast that requires significant navigation by any company in the healthcare space. Whether you’re a Big Pharma, a small biotech or an ...
Dealmaking is a hallmark of the pharma industry. Whether to access innovative therapies, expand into new areas or fill a gap left from a failure in the clinic, pipelines need ...
Markella is part of Evaluate’s competitive intelligence (CI) consulting practice, where she works on a wide range of projects to support CI teams in pharma companies to ensure they stay ...
The number of cell and gene therapy (C>)-based treatments in development has increased significantly over the last two decades and can be expected to continue, driven by the modality-specific market ...
Our focus was on the 2024 Preview, our annual report that looks at the top drugs, companies, potential launches and much more for the year ahead. In the webinar, our ...
